Trial results for the SAFE-2 study, investigating the Colovac device for colorectal cancer, were posted on ClinicalTrials.gov on 2025-07-03. The study, which was terminated, enrolled 18 participants and reported that 7 participants in the Colovac group avoided ostomy compared to 0 in the standard of care group.
Background
Colorectal cancer is a common malignancy, often requiring surgical intervention such as lower anterior resection. A critical challenge after this procedure is the healing of the colorectal anastomosis, where the two ends of the bowel are reconnected. Complications like anastomotic leakage can lead to severe morbidity, often necessitating a temporary or permanent ostomy (colostomy or ileostomy). Devices designed to protect the anastomosis aim to reduce these complications and improve patient quality of life by potentially avoiding the need for an ostomy.
Trial design
The SAFE-2 Pivotal Study (NCT05010850) was a randomized trial, designated as Phase NA, that was terminated after enrolling 18 participants. The study aimed to assess the safety and effectiveness of the Colovac device in providing temporary protection of the anastomosis in subjects undergoing lower anterior resection for conditions including Colorectal Cancer, Rectal Cancer, Rectal Tumor, and Rectal/Anal conditions. Participants were randomized to either receive the Colovac device or standard of care.
Key results
The trial reported key measurements related to ostomy avoidance and major safety complications:
- For the outcome of "Avoidance of Ostomy":
- In the Colovac group, 7 participants avoided ostomy.
- In the Standard of Care group, 0 participants avoided ostomy.
- For the outcome of "Safety Major Complications":
- In the Colovac group, 3 participants experienced major complications.
- In the Standard of Care group, 2 participants experienced major complications.
What this means
The results from this terminated trial suggest a potential signal for the Colovac device in preventing ostomy in patients undergoing lower anterior resection for colorectal cancer, with 7 participants in the Colovac group avoiding ostomy compared to 0 in the standard of care group. However, it is important to note that the Colovac group also reported a higher number of major safety complications, with 3 participants experiencing them compared to 2 in the standard of care group. The small sample size of 18 participants and the termination of the study mean these findings should be interpreted with caution, and no definitive conclusions about the device's overall safety and effectiveness can be drawn from this limited dataset.
Source
The information for this condition update was obtained from ClinicalTrials.gov, a public database of clinical studies. Trial results for the study NCT05010850, titled "SafeHeal Colovac Colorectal Anastomosis Protection Device Evaluation (SAFE-2) Pivotal Study", were posted on 2025-07-03 on clinicaltrials.gov.